1. The 20-Year Myth: Why Nominal Term Is the Wrong Starting Number Ask most people in the pharmaceutical business how […]

Every dollar a brand-name manufacturer recovers in the market traces back, in some way, to the strength and duration of

Executive Summary Patent Term Extension (PTE) under 35 U.S.C. § 156 is one of the most financially consequential and systematically

1. The Economics of Drug Repurposing: Why Eroom’s Law Changes Everything {#section-1} 1.1 What Drug Repurposing Actually Means Drug repurposing,

The AI-Native Pharmaceutical Pipeline: Technical Architectures and Economic Valuation The pharmaceutical industry faces a productivity crisis defined by Eroom’s Law,

A technically dense deep dive for pharma IP teams, R&D leads, and institutional investors, covering the full financing architecture, patent

Biologic Economics: Why These Drugs Cost This Much Biologics sit at the apex of pharmaceutical complexity. Unlike a small-molecule drug,

1. Executive Summary Drug development costs roughly double every nine years. That is Eroom’s Law, the inverse of Moore’s Law,

1. Why Excipient Switching Deserves a Seat at the Strategy Table {#1} Pharmaceutical companies spend millions optimizing the active pharmaceutical